Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 566Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
REVIEW ARTICLE
Year : 2016  |  Volume : 7  |  Issue : 2  |  Page : 68-74

MicroRNA therapeutics: Discovering novel targets and developing specific therapy

Ajay Francis Christopher, Raman Preet Kaur, Gunpreet Kaur, Amandeep Kaur, Vikas Gupta, Parveen Bansal
Division of Clinical Research, University Centre of Excellence in Research, Baba Farid University of Health Science, Faridkot, Punjab, India

Date of Web Publication31-Mar-2016

Correspondence Address:
Parveen Bansal
Division of Clinical Research, University Centre of Excellence in Research, Baba Farid University of Health Science, Faridkot - 151 203, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.179431

Rights and Permissions
   Abstract 


MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression in diverse biological process. They act as intracellular mediators that are necessary for various biological processes. MicroRNAs targeting pathways of human disease provide a new and potential powerful candidate for therapeutic intervention against various pathological conditions. Even though, the information about miRNA biology has significantly enriched but we still do not completely understand the mechanism of miRNA gene regulation. Various groups across the globe and pharmaceutical companies are conducting research and developments to explore miRNA based therapy and build a whole new area of miroRNA therapeutics. Consequently, few miRNAs have entered the preclinical and clinical stage and soon might be available in the market for use in humans.

Keywords: Clinical stage, gene expression, microRNA, therapeutics


How to cite this article:
Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res 2016;7:68-74

How to cite this URL:
Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res [serial online] 2016 [cited 2022 May 28];7:68-74. Available from: https://www.picronline.org/text.asp?2016/7/2/68/179431




   Introduction Top


MicroRNAs (miRNAs) are small noncoding RNAs that are approximately 20–25 nucleotides in length. They regulate the expression of multiple target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs. These microRNAs block the translation or they can cause direct degradation of their target messenger RNAs. miRNAs do not require perfect complementarity for target recognition, so a single miRNA is responsible for the regulation of multiple messenger RNAs. Although miRNAs exert slight effects on each individual messenger RNA target, the combined effect is significant and produces measurable phenotypic results. miRNAs play integral roles in several biological processes, including immune modulation, metabolic control, neuronal development, cell cycle, muscle differentiation, and stem cell differentiation. Most miRNAs are conserved across multiple animal species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways and processes.

It has been seen that expressions of many miRNAs are altered in different diseases. Some miRNAs are overexpressed whereas some are underexpressed in a particular disease giving rise to signature miRNA pattern. With the discovery of miRNAs and its critical role as regulators in various diseases, it is quiet relevant to explore and understand the possibility of using miRNA as therapeutic agents. Recent studies in animals and humans conducted in different laboratories present data that strengthen the candidature of miRNAs to establish the candidature of miRNAs to establish as a novel class of drugs, i.e., miRNA therapeutics.[1],[2] The miRNAs possess a unique characteristic which is very attractive in terms of drug development, i.e.,. they are small, with known sequences and are often conserved among species. Based on antisense technology, very potent oligonucleotide targeted against miRNA known as anti-miR is being developed. An ideal design for an active synthetic miRNA is that it should bind to its respective targeted miRNA with high affinity and specificity.

This review will focus on miRNA and its biogenesis, importance in various diseases, the potential of using miRNAs as a therapeutic modality, and finally an update on the status of clinical trials.


   History Top


In 1993, first miRNA was discovered during a study on gene Lin-4 of Caenorhabditiselegans.[3] It was seen after the isolation of Lin-4 that the gene encodes a protein that binds to 3′ UTR of Lin-14 mRNA and hence prevents translation of Lin-14. In 2000, second small RNA let-7 was discovered; it repressed Lin-4 mRNA to promote a later developmental transition in C.elegans.[4] Subsequently, it was discovered that lin-4 and let-7 were found in Drosophila and human cells, respectively. Most of the RNAs of this class resembled the Lin-4 and let-7 RNAs, however they had no role in regulating the timing of development thereby suggesting that most of miRNAs were involved in other types of regulatory pathways. Following this, the term “miRNA” to refer to this class of small regulatory RNAs came into existence.

MicroRNAs: Tiny master regulators

The miRNAs are known to be expressed in most organisms from plant to vertebrates (including viruses) and are conserved in all organisms. They regulate gene expression by either degrading or making the targeted mRNAs “silence” rendering their translation into proteins. The miRNAs regulate gene expressions, which affect various biological processes such as cell proliferation, differentiation, survival, and motility. The miRNAs do not require perfect complementarity for target recognition, so a single miRNA is able to regulate multiple mRNAs. On average, a given miRNA can regulate several hundred transcripts whose effector molecules function at various sites within cellular pathways and networks. Consequently, miRNAs are able to switch instantly between cellular programs and are therefore often viewed as tiny master regulators of the human genome.

The miRNAs are predicted using different approaches such as experimental method, computational approach, expressed sequence tag, and genomic survey sequence analysis. However, only a few predicted miRNAs have undergone validation experimentally. Computational analysis indicates that the total number of miRNAs could be more that 1% of total translated genes and more than 30% of protein-coding genes may be targeted by miRNAs.

MicroRNA biogenesis

The miRNA genes are expressed in the cell nucleus. About 70% of the human miRNAs are transcribed from introns and/or exons. A brief overview of miRNA biogenesis is shown in [Figure 1].
Figure 1: Schematic overview of microRNA biogenesis

Click here to view


Association of microRNA with various diseases

miRNAs are becoming increasingly recognized as their expressions are altered in different diseases such as cancer, hepatitis C infection, myocardial infarction, and metabolic disease. Some miRNAs are overexpressed whereas some are underexpressed in a particular disease giving rise to a signature miRNA pattern. In case of tumors, the miRNAs which are overexpressed may be considered as oncogenes and are called “oncomirs.”[5] They are considered to be involved in tumor development by reciprocally inhibiting tumor suppressor genes (genes that control cell differentiation and apoptosis), for example, miR-17–192 is significantly overexpressed in lung cancer and several other lymphomas. On the other hand, expression of some miRNAs (tumor suppressor) is lower in cancerous cells and usually prevents tumor development by negatively inhibiting oncogenes, for example, let-7 is a tumor suppressor miRNA and aberrant expression of let-7 results in oncogenic loss of differentiation.[6] An overview of the association of signature miRNA with some disease condition is given in [Table 1]. The signature miRNAs associated with disease are discussed in the following sections.
Table 1: Differentially expressed microRNAs (signature microRNAs) in various diseases

Click here to view


MiR-122 in hepatitis C virus

MiR-122 is the most commonly found miRNA in the adult liver and plays a key role in liver biology that includes development, differentiation, homeostasis, and functions. It controls the metabolism, i.e., cholesterol biosynthesis. miR-122 is involved in the replication of hepatitis C virus (HCV). It binds to the viral genome and enhances viral translation and replication. The binding site in the 5′ end of HCV genome provided the evidence of the direct role of miR-122 into HCV replication.[7],[8]

MiR-33a in metabolic disease

miR-33a targets genes involved in cholesterol export such as the adenosine triphosphate-binding cassette (ABC) transporters ABCA1 and ABCG1 and the endolysosomal transport protein Niemann-Pick C1 (Npc1). In agreement with the regulation of ABCA1 by miR-33, modulation of miR-33a levels results in encompassing effects in cholesterol efflux in macrophages thus suggesting that miR-33 may participate in the regulation of high-density lipoprotein (HDL) levels in vivo. Indeed, three independent studies have demonstrated that endogenous inhibition of miR-33 using different strategies leads to a significant increase in hepatic ABCA1 expression and plasma HDL levels, and these findings were later confirmed in the miR-33 knockout mice.[9]

MiR-155 in inflammatory disease

miR-155 is overexpressed in atopic dermatitis and contributes to chronic skin inflammation by increasing the proliferative response of T-helper cells through the downregulation of cytotoxic T-lymphocyte antigen-4.[10] In autoimmune disorders such as rheumatoid arthritis, miR-155 showed higher expression in patients' tissues and synovial fibroblasts.[11] In multiple sclerosis, increased expression of miR-155 has also been measured in peripheral and central nervous system-resident myeloid cells, including circulating blood monocytes and activated microglia. Overexpression of miR-155 leads to chronic inflammatory state in human.

MiR-10b in glioblastoma

The levels of miR-10b are upregulated in human glioblastoma tissues, glioblastoma cell, and stem cell lines as compared to normal human tissues or astrocytes [12] Inhibition of miR-10b inhibits glioblastoma proliferation, reduces cell invasion, and migration in glioblastoma cell and stem cell lines whereas overexpression of miR-10b induced cell migration and invasion.

MiR-33 in atherosclerosis

Plasma HDL levels have a protective role in atherosclerosis. miR-33, an intronic miRNA located within the SREBF2 gene, suppresses the expression of the cholesterol transporter ABC transporter A1 (ABCA1) and lowers HDL levels. Conversely, mechanisms that inhibit miR-33 increase ABCA1 and circulating HDL levels, suggesting that antagonism of miR-33 may be atheroprotective. In a study, mice deficient for the low-density lipoprotein receptor (LDLr–/– mice), with established atherosclerotic plaques treated with anti-miR33 for 4 weeks, showed an increase in circulating HDL levels and enhanced reverse cholesterol transport to the plasma, liver, and feces.[13] Consistent with this, anti-miR33-treated mice showed reductions in plaque size and lipid content, increased markers of plaque stability, and decreased inflammatory gene expression. Notably, in addition to raising ABCA1 levels in the liver, anti-miR33 oligonucleotides directly targeted the plaque macrophages, in which they enhanced ABCA1 expression and cholesterol removal. Thus, raising HDL levels by anti-miR33 oligonucleotide treatment promotes reverse cholesterol transport and atherosclerosis regression.

MiR-21 in hepatocellular carcinoma

Deregulated expressions of several miRNAs were found to correlate with the pathologic and clinical characteristics of hepatocellular carcinoma HCC.[14] The miRNA microarray analysis has revealed that miR-21 was dramatically elevated in HCC tumor cells, with significant reductions of the expressions of several tumor suppressor genes, including PTEN, PDCD4, RECK, and TPM1 (PTEN).[15] MAP2K3 has also been identified as a novel direct target of miR-21. The study of loss-of-function of miR-21 by transduction of miR-21 sponge in HepG2 cells indicated that miR-21 might regulate cell proliferation, apoptosis, and invasiveness partially by targeting MAP2K3.

MicroRNA as therapeutic target and tool

The expression of miRNAs is altered in various diseases and it is now feasible to manipulate miRNA expression by injecting miRNAs similar to the use of antisense mRNAs and RNAi (widely used techniques for investigating gene function and in gene therapy).[16] As the activation of oncogenes could cause cancer, artificial antisense miRNAs could be synthesized and employed to block their targeted oncomirs to prevent the formation of cancer. However, various critical prerequisite data must be available, for example, identification of signature miRNAs, their mechanism of action, applicability by RNAi, delivery of miRNAs, and their active form in vivo. Once this information is available, miRNA will have a bright future and become a novel therapeutic tool. The process of building miRNA therapeutics is similar to drug discovery and development. Following steps are involved in the discovery and development of miRNA therapeutics [Figure 2]:
Figure 2: Process of microRNA discovery and development

Click here to view


  • Identification of signature miRNA (done by miRNA profiling in disease)
  • Validation of signature miRNA (loss/gain of function studies in vitro and in animal models)
  • Pharmacological analysis (in vivo miRNA delivery studies, pharmacokinetics/pharmacodynamics, (absorption, distribution, metabolism, excretion, and toxicity studies)
  • Clinical trials (studies on the evaluation of efficacy and safety).


Strategies for microRNA manipulation

There are two main strategies to manipulate miRNAs which are dependent on whether the targeted miRNA expression needs to be downregulated or to re-introduce miRNAs function to restore loss of function. The strategies for miRNA manipulation are summarized in [Table 2].
Table 2: Various microRNAs-based therapeutic strategies investigated in cancer

Click here to view


Antisense inhibition of mature microRNA (inhibiting oncomirs)

The miRNA antagonists are oligonucleotides containing the complementary sequences of endogenous miRNAs. Antisense oligonucleotide (AMO), also called antagomir, is the most commonly used anti-miRNA antisense oligomer.[2] The locked nucleic acid possess stronger affinity to targeted miRNA, more resistant to nucleases, and have lower toxicity. The peptide nucleic acid (PNA) is an artificial synthesized peptide-structured polymer and is similar to DNA and RNA. The PNA binds the targeted nucleotide more tightly than the nucleotide/nucleotide binding, are relatively stable, have low toxicity, and could be administered systematically.[17] The latest new strategy available is miRNA sponge and miRNA masking. The miRNA sponge downregulates the targeted miRNA and possesses multiple complementary sites to the targeted miRNA,[18] whereas miRNA masking have complimentary miRNA binding site in the 3′ UTR of the target mRNA to inhibit competitively and decreases the activity of endogenous miRNA. The various antisense inhibitors employed for downregulating various miRNAs are depicted in [Table 3].
Table 3: Various methods available for the delivery of microRNAs

Click here to view


Replacement of microRNAs

In diseases such as cancer, expression levels of downregulated miRNAs or altered miRNA could be done using vector, overexpressing the targeted miRNA or by the transfection of double-stranded miRNAs. Therefore, studies have been conducted by introducing artificial double-stranded miRNA (mimic of targeted downregulated miRNA). For example, overexpression of downregulated miR-26a in hepatocellular carcinoma (HCC) in mouse liver resulted in inhibition of cancer proliferation and initiation of apoptosis. Subsequently in another study, the downregulated miR-34a level was increased by delivering artificial miR-34a with NOV340 liposome in an orthotopic model of HCC.[19] This resulted in significant tumor reduction, prolonged survival, and disease protection in animals.

Patent and clinical trial status of microRNA therapeutics

There is a great excitement regarding miRNA use as therapeutic entities. In terms of scientific perspective, miRNA represents a novel and an attractive target which could manipulate the body functions. Consequently, there has been considerable increase in the number of patent applications filed over the decade. The annual number of US and European published patent applications and issued patents related to miRNAs is close to 500. A snapshot of the current development status of miRNA-based therapeutics is summarized in [Table 4].
Table 4: Overview of microRNAs therapeutics development status

Click here to view


Future perspectives of microRNA therapeutics

The functionality of miRNA in controlling diverse gene expression in cancer and various other important diseases makes miRNA an ideal candidate for therapeutic applications. Recent data demonstrate that the miRNA expression is altered in various human diseases and its selective modulation through antisense inhibition or replacement could significantly affect the prognosis of a disease. With the technological advancement and ease of administration of miRNA through local or parenteral injection routes and its sufficient uptake in the tissue without the need of developing formulation gives miRNA therapeutics an extra edge. We hope that with increasing research and development on miRNA, increase in the filed patents and increased attention and interest of the biotechnology companies in miRNA-based therapeutics would follow suit. This promises the availability of miRNA therapeutics in the market in the coming years for the treatment of various diseases.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30.  Back to cited text no. 1
    
2.
Czech MP. MicroRNAs as therapeutic targets. N Engl J Med 2006;354:1194-5.  Back to cited text no. 2
    
3.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.  Back to cited text no. 3
    
4.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.  Back to cited text no. 4
    
5.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.  Back to cited text no. 5
    
6.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.  Back to cited text no. 6
    
7.
Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008;4:77-85.  Back to cited text no. 7
    
8.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81.  Back to cited text no. 8
    
9.
Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010;107:12228-32.  Back to cited text no. 9
    
10.
Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008;28:630-8.  Back to cited text no. 10
    
11.
Li X, Tian F, Wang F. Rheumatoid arthritis-associated microRNA-155 targets SOCS1 and upregulates TNF-a and IL-1ß in PBMCs. Int J Mol Sci 2013;14:23910-21.  Back to cited text no. 11
    
12.
Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 2013;112:153-63.  Back to cited text no. 12
    
13.
Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-31.  Back to cited text no. 13
    
14.
Aravalli RN. Development of MicroRNA Therapeutics for hepatocellular carcinoma. Diagnostics (Basel) 2013;3:170-91.  Back to cited text no. 14
    
15.
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.  Back to cited text no. 15
    
16.
Vidal L, Blagden S, Attard G, de Bono J. Making sense of antisense. Eur J Cancer 2005;41:2812-8.  Back to cited text no. 16
    
17.
Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KG, et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 2010;38:4466-75.  Back to cited text no. 17
    
18.
Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012;11:316-22.  Back to cited text no. 18
    
19.
Bader AG. miR-34 – A microRNA replacement therapy is headed to the clinic. Front Genet 2012;3:120.  Back to cited text no. 19
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]


This article has been cited by
1 miRNA signatures in diabetic retinopathy and nephropathy: delineating underlying mechanisms
Prabhsimran Kaur, Sushil Kotru, Sandeep Singh, Anjana Munshi
Journal of Physiology and Biochemistry. 2022;
[Pubmed] | [DOI]
2 Clinical and immunological aspects of microRNAs in neonatal sepsis
Ahlam Fatmi, Nafissa Chabni, María Cernada, Máximo Vento, María González-López, Mourad Aribi, Federico V. Pallardó, José Luis García-Giménez
Biomedicine & Pharmacotherapy. 2022; 145: 112444
[Pubmed] | [DOI]
3 Exosomal mediated signal transduction through artificial microRNA (amiRNA): A potential target for inhibition of SARS-CoV-2
Chithravel Vadivalagan, Anushka Shitu, Siva Kamalakannan, Ruei-Ming Chen, Ángel Serrano-Aroca, Vijay Mishra, Alaa A.A. Aljabali, Sachin Kumar Singh, Dinesh Kumar Chellappan, Gaurav Gupta, Kamal Dua, Mohamed El-Tanani, Murtaza M. Tambuwala, Anand Krishnan
Cellular Signalling. 2022; : 110334
[Pubmed] | [DOI]
4 Association between miRNAs expression and multiple sclerosis pathogenesis: A novel therapeutic approach
Hanieh Beyrampour-Basmenj, Mohammad Rahmati, Mohammad Pourhassan Moghamddam, Mohammad Ebrahimi Kalan, Mohammadreza Alivand, Zeynab Aliyari-Serej, Parastou Nastarin, Mohammadhassan Omrani, Sina Khodakarimi, Abbas Ebrahimi-Kalan
Gene Reports. 2022; 26: 101457
[Pubmed] | [DOI]
5 miR-383 Regulates Hepatic Lipid Homeostasis and Response to Dengue Virus Infection
Nadine Ahmed, Noreen Ahmed, John Paul Pezacki
ACS Infectious Diseases. 2022;
[Pubmed] | [DOI]
6 Endogenous controls and microRNA profile in female patients with obstructive sleep apnea
Andrea Zapater, Iván D. Benítez, Fernando Santamaria-Martos, Lucía Pinilla, Adriano Targa, David De Gonzalo-Calvo, Gerard Torres, Olga Mínguez, Anunciación Cortijo, Mireia Dalmases, Ferrán Barbé, Manuel Sánchez-de-la-Torre
Scientific Reports. 2022; 12(1)
[Pubmed] | [DOI]
7 Exosomes as Nanocarriers for Theragnostic miRNA Markers in Nonsmall Cell Lung Cancer Therapy
Ziyu Jiang, Yun He, Wenlong Ding, Siyao Zhu, Qinyuan Li, Xiuchun Sun, Meiguang Bian, Jiege Huo, Haisheng Qian
Journal of Nanomaterials. 2022; 2022: 1
[Pubmed] | [DOI]
8 Hypothalamic miR-1983 Targets Insulin Receptor ß and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin
Jennifer A Chalmers, Prasad S Dalvi, Neruja Loganathan, Emma K McIlwraith, Leigh Wellhauser, Anaies Nazarians-Armavil, Judith A Eversley, Haneesha Mohan, Priska Stahel, Satya Dash, Michael B Wheeler, Denise D Belsham
Endocrinology. 2022; 163(1)
[Pubmed] | [DOI]
9 In vitro elimination of EL4 cancer cells from spermatogonia stem cells by miRNA-143- and 206-loaded folic acid conjugated PLGA nanoparticles
Azar Shams, Ronak Shabani, Hamidreza Asgari, Mahdi Karimi, Mohammad Najafi, Mohammad Asghari-Jafarabadi, Seyed Mohsen Razavi, Seyed Rouhollah Miri, Mehdi Abbasi, Amirhossein Mohammadi, Morteza Koruji
Nanomedicine. 2022;
[Pubmed] | [DOI]
10 Aquaglyceroporin Modulators as Emergent Pharmacological Molecules for Human Diseases
Catarina Pimpão, Darren Wragg, Inês V. da Silva, Angela Casini, Graça Soveral
Frontiers in Molecular Biosciences. 2022; 9
[Pubmed] | [DOI]
11 Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
Navid Shomali, Marwah Suliman Maashi, Behzad Baradaran, Amin Daei Sorkhabi, Aila Sarkesh, Hamed Mohammadi, Maryam Hemmatzadeh, Faroogh Marofi, Siamak Sandoghchian Shotorbani, Mostafa Jarahian
Frontiers in Immunology. 2022; 13
[Pubmed] | [DOI]
12 Novel Therapies for Alport Syndrome
Efren Chavez, Juanly Rodriguez, Yelena Drexler, Alessia Fornoni
Frontiers in Medicine. 2022; 9
[Pubmed] | [DOI]
13 Sequence Requirements for miR-424-5p Regulating and Function in Cancers
Jiangying Xuan, Yingxia Liu, Xiaoping Zeng, Hongmei Wang
International Journal of Molecular Sciences. 2022; 23(7): 4037
[Pubmed] | [DOI]
14 Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma
Yu-Cheng Lee, Cheng-Han Lin, Wei-Lun Chang, Wen-Der Lin, Jhih-Kai Pan, Wei-Jan Wang, Bor-Chyuan Su, Hsien-Hui Chung, Chen-Hsun Tsai, Forn-Chia Lin, Wen-Ching Wang, Pei-Jung Lu
International Journal of Molecular Sciences. 2022; 23(8): 4367
[Pubmed] | [DOI]
15 MicroRNAs miR-451a and Let-7i-5p Profiles in Circulating Exosomes Vary among Individuals with Different Sickle Hemoglobin Genotypes and Malaria
Keri Oxendine Harp, Alaijah Bashi, Felix Botchway, Yvonne Dei-Adomakoh, Shareen A. Iqbal, Michael D. Wilson, Andrew A. Adjei, Jonathan K. Stiles, Adel Driss
Journal of Clinical Medicine. 2022; 11(3): 500
[Pubmed] | [DOI]
16 miR-24 Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells
Pasquale Mone,Jessica Gambardella,Xujun Wang,Stanislovas S. Jankauskas,Alessandro Matarese,Gaetano Santulli
Non-Coding RNA. 2021; 7(1): 9
[Pubmed] | [DOI]
17 Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review
Shadab Md, Nabil A. Alhakamy, Shahid Karim, Gamal A Gabr, Mohammad Kashif Iqubal, Samar S. A. Murshid
Pharmaceutics. 2021; 13(12): 2120
[Pubmed] | [DOI]
18 Expression of Selected microRNAs in Migraine: A New Class of Possible Biomarkers of Disease?
Lara Ahmad, Chiara Demartini, Michele Corrado, Gloria Vaghi, Elisa Maria Piella, Marta Allena, Anna Maria Zanaboni, Rosaria Greco, Cristina Tassorelli, Roberto De Icco
Processes. 2021; 9(12): 2199
[Pubmed] | [DOI]
19 The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review
Noora Karim Ahangar,Nima Hemmat,Mohammad Khalaj-Kondori,Mahdi Abdoli Shadbad,Hani Sabaie,Ahad Mokhtarzadeh,Nazila Alizadeh,Afshin Derakhshani,Amir Baghbanzadeh,Katayoun Dolatkhah,Nicola Silvestris,Behzad Baradaran
International Journal of Molecular Sciences. 2021; 22(5): 2652
[Pubmed] | [DOI]
20 Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review
Farha Ramzan,Mark H. Vickers,Richard F. Mithen
International Journal of Molecular Sciences. 2021; 22(9): 5047
[Pubmed] | [DOI]
21 Dysregulation of microRNA and Intracerebral Hemorrhage: Roles in Neuroinflammation
Hisham Kashif,Dilan Shah,Sangeetha Sukumari-Ramesh
International Journal of Molecular Sciences. 2021; 22(15): 8115
[Pubmed] | [DOI]
22 miRNAs as Therapeutic Tools in Alzheimer’s Disease
Chang Youn Lee, In Soo Ryu, Jin-Hyeob Ryu, Hyun-Jeong Cho
International Journal of Molecular Sciences. 2021; 22(23): 13012
[Pubmed] | [DOI]
23 MicroRNA-30b Is Both Necessary and Sufficient for Interleukin-21 Receptor-Mediated Angiogenesis in Experimental Peripheral Arterial Disease
Tao Wang, Liang Yang, Mingjie Yuan, Charles R. Farber, Rosanne Spolski, Warren J. Leonard, Vijay C. Ganta, Brian H. Annex
International Journal of Molecular Sciences. 2021; 23(1): 271
[Pubmed] | [DOI]
24 Where the Aryl Hydrocarbon Receptor Meets the microRNAs: Literature Review of the Last 10 Years
Geonildo Rodrigo Disner, Monica Lopes-Ferreira, Carla Lima
Frontiers in Molecular Biosciences. 2021; 8
[Pubmed] | [DOI]
25 The Influence of miRNAs on Radiotherapy Treatment in Prostate Cancer – A Systematic Review
Sílvia Soares,Susana G. Guerreiro,Natália Cruz-Martins,Isabel Faria,Pilar Baylina,Maria Goreti Sales,Miguel A. Correa-Duarte,Rúben Fernandes
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
26 The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer
Hussein Al-Akhrass,Niki Christou
Cancers. 2021; 13(12): 2916
[Pubmed] | [DOI]
27 Co-Expression Network Analysis of MicroRNAs and Proteins in Severe Traumatic Brain Injury: A Systematic Review
Claire Osgood,Zubair Ahmed,Valentina Di Pietro
Cells. 2021; 10(9): 2425
[Pubmed] | [DOI]
28 RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics
Guruprasadh Swaminathan,Aisha Shigna,Aviral Kumar,Vishnu Vardhan Byroju,Varsha Reddy Durgempudi,Lekha Dinesh Kumar
Frontiers in Nanotechnology. 2021; 3
[Pubmed] | [DOI]
29 Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
Qinhan Li,Zhenan Zhang,Yu Fan,Qian Zhang
Frontiers in Genetics. 2021; 11
[Pubmed] | [DOI]
30 Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
Jeong-An Gim,Soo Min Bang,Young-Sun Lee,Yoonseok Lee,Sun Young Yim,Young Kul Jung,Hayeon Kim,Baek-Hui Kim,Ji Hoon Kim,Yeon Seok Seo,Hyung Joon Yim,Jong Eun Yeon,Soon Ho Um,Kwan Soo Byun,Matias A. Avila
PLOS ONE. 2021; 16(8): e0255822
[Pubmed] | [DOI]
31 A Review on the Role of Nanosensors in Detecting Cellular miRNA Expression in Colorectal Cancer
Koyeli Girigoswami, Agnishwar Girigoswami
Endocrine, Metabolic & Immune Disorders - Drug Targets. 2021; 21(1): 12
[Pubmed] | [DOI]
32 Molecular insights into the role of genetic determinants of congenital hypothyroidism
Yedukondalu Kollati,Radha Rama Devi Akella,Shaik Mohammad Naushad,Rajesh K. Patel,G. Bhanuprakash Reddy,Vijaya R. Dirisala
Genomics & Informatics. 2021; 19(3): e29
[Pubmed] | [DOI]
33 Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
Johannes Lorenz Berg,Bianca Perfler,Stefan Hatzl,Marie-Christina Mayer,Sonja Wurm,Barbara Uhl,Andreas Reinisch,Ingeborg Klymiuk,Sascha Tierling,Gudrun Pregartner,Gerhard Bachmaier,Andrea Berghold,Klaus Geissler,Martin Pichler,Gerald Hoefler,Herbert Strobl,Albert Wölfler,Heinz Sill,Armin Zebisch
Clinical Epigenetics. 2021; 13(1)
[Pubmed] | [DOI]
34 Serum miR-222 is independently associated with atrial fibrillation in patients with degenerative valvular heart disease
Hualan Zhou,Sen Lin,Xia Li,Dianxuan Guo,Yun Wang,Youdong Hu
BMC Cardiovascular Disorders. 2021; 21(1)
[Pubmed] | [DOI]
35 Circulating Blood miR-155 and miR-21 Promote the Development of Acute Pancreatitis and Can Be Used to Assess the Risk Stratification of Pancreatitis
Lan Hu, Dongdong Han, Diao Yu, Dongji Ao, Zhengyi Yang, Kalidoss Rajakani
Journal of Healthcare Engineering. 2021; 2021: 1
[Pubmed] | [DOI]
36 Deficiency of MicroRNA-181a Results in Transcriptome-Wide Cell-Specific Changes in the Kidney and Increases Blood Pressure
Madeleine R. Paterson,Kristy L. Jackson,Malathi S.I. Dona,Gabriella E. Farrugia,Bruna Visniauskas,Anna M.D. Watson,Chad Johnson,Minolfa C. Prieto,Roger G. Evans,Fadi J. Charchar,Alexander R. Pinto,Francine Z. Marques,Geoffrey A. Head
Hypertension. 2021;
[Pubmed] | [DOI]
37 Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation
Christopher M. Bobba,Qinqin Fei,Vasudha Shukla,Hyunwook Lee,Pragi Patel,Rachel K. Putman,Carleen Spitzer,MuChun Tsai,Mark D. Wewers,Robert J. Lee,John W. Christman,Megan N. Ballinger,Samir N. Ghadiali,Joshua A. Englert
Nature Communications. 2021; 12(1)
[Pubmed] | [DOI]
38 microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials
Yeganeh Rastgar Rezaei,Reza Zarezadeh,Saba Nikanfar,Hajar Oghbaei,Nahideh Nazdikbin,Zahra Bahrami-Asl,Nosratollah Zarghami,Yadollah Ahmadi,Amir Fattahi,Mohammad Nouri,Ralf Dittrich
Systems Biology in Reproductive Medicine. 2021; : 1
[Pubmed] | [DOI]
39 Downregulation of microRNA-200c-3p alleviates the aggravation of venous thromboembolism by targeting serpin family C member 1
Xiaorong Jian, Dehua Yang, Li Wang, Hongxiang Wang
Bioengineered. 2021;
[Pubmed] | [DOI]
40 MicroRNAs affect GPCR and Ion channel genes needed for influenza replication
Nichole Orr-Burks, Jackelyn Murray, Kyle V. Todd, Abhijeet Bakre, Ralph A. Tripp
Journal of General Virology . 2021; 102(11)
[Pubmed] | [DOI]
41 Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells
Yalda Khazaei-Poul,Samaneh Shojaei,Ameneh Koochaki,Hossein Ghanbarian,Samira Mohammadi-Yeganeh
Life Sciences. 2021; : 120015
[Pubmed] | [DOI]
42 MicroRNAs expression changes coincide with low or high grade of squamous intraepithelial lesion infected by HPV-16
Sara Norouzi,Ali Farhadi,Ehsan Farzadfard,Mojgan Akbarzade-Jahromi,Neda Ahmadzadeh,Mahboobeh Nasiri,Gholamhossein Tamaddon
Gene Reports. 2021; : 101186
[Pubmed] | [DOI]
43 Lipids and Lipid Derivatives for RNA Delivery
Yuebao Zhang,Changzhen Sun,Chang Wang,Katarina E. Jankovic,Yizhou Dong
Chemical Reviews. 2021;
[Pubmed] | [DOI]
44 Emerging role of microRNAs as novel targets of antidepressants
Aarthi Manoharan, Abialbon Paul
Asian Journal of Psychiatry. 2021; 66: 102906
[Pubmed] | [DOI]
45 Comprehensive Transcriptome Analyses in Sea Louse Reveal Novel Delousing Drug Responses Through MicroRNA regulation
Gustavo Núñez-Acuña,Valentina Valenzuela-Muñoz,Diego Valenzuela-Miranda,Cristian Gallardo-Escárate
Marine Biotechnology. 2021;
[Pubmed] | [DOI]
46 Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?
Patrick Malcolm Siegel,Judith Schmich,Georg Barinov,István Bojti,Christopher Vedecnik,Novita Riani Simanjuntak,Christoph Bode,Martin Moser,Karlheinz Peter,Philipp Diehl
Journal of Thrombosis and Thrombolysis. 2020;
[Pubmed] | [DOI]
47 MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside
Margherita Ratti,Andrea Lampis,Michele Ghidini,Massimiliano Salati,Milko B. Mirchev,Nicola Valeri,Jens C. Hahne
Targeted Oncology. 2020;
[Pubmed] | [DOI]
48 Targeting SARS CoV2 (Indian isolate) genome with miRNA: An in silico study
Arpita Devi,Nyshadham S. N. Chaitanya
IUBMB Life. 2020;
[Pubmed] | [DOI]
49 miR-129 blocks secondary hyperparathyroidism-inducing Fgf23/aKlotho signaling in mice with chronic kidney disease
Mingzhi Xu,Hong Li,Yafei Bai,Jiqing He,Ruman Chen,Na An,Yongyong Li,Yishan Dong
The American Journal of the Medical Sciences. 2020;
[Pubmed] | [DOI]
50 Nucleic acid hybridization on a plasmonic nanointerface of optical microfiber enables ultrahigh-sensitive detection and potential photothermal therapy
Yunyun Huang,Pengwei Chen,He Liang,Aoxiang Xiao,Shengkang Zeng,Bai-Ou Guan
Biosensors and Bioelectronics. 2020; 156: 112147
[Pubmed] | [DOI]
51 microRNAs: New-Age Panacea in Cancer Therapeutics
Neelanjana Sarkar,Arun Kumar
Indian Journal of Surgical Oncology. 2020;
[Pubmed] | [DOI]
52 Extracellular vesicles, microRNA and the preimplantation embryo: non-invasive clues of embryo well-being
David Connor Hawke,Andrew John Watson,Dean Harvey Betts
Reproductive BioMedicine Online. 2020;
[Pubmed] | [DOI]
53 Epigenetic regulation of miR-29a/miR-30c/DNMT3A axis controls SOD2 and mitochondrial oxidative stress in human mesenchymal stem cells
Yi-deun Jung,Seul-Ki Park,Dayeon Kang,Supyong Hwang,Myoung-Hee Kang,Seung-Woo Hong,Jai-Hee Moon,Jae-Sik Shin,Dong-Hoon Jin,Dalsan You,Joo-Yong Lee,Yun-Yong Park,Jung Jin Hwang,Choung Soo Kim,Nayoung Suh
Redox Biology. 2020; 37: 101716
[Pubmed] | [DOI]
54 Genetically Encoded Reporter Genes for MicroRNA Imaging in Living Cells and Animals
Yingzhuang Song,Zhijing Xu,Fu Wang
Molecular Therapy - Nucleic Acids. 2020; 21: 555
[Pubmed] | [DOI]
55 New possible pharmacological targets for statins and ezetimibe
Mateusz Niedzielski,Marlena Broncel,Paulina Gorzelak-Pabis,Ewelina Wozniak
Biomedicine & Pharmacotherapy. 2020; 129: 110388
[Pubmed] | [DOI]
56 Circular RNA Circ_0000064 promotes the proliferation and fibrosis of mesangial cells via miR-143 in diabetic nephropathy
Xiaoxu Ge,Liuqing Xi,Qianqian Wang,Huihua Li,Lili Xia,Zhen Cang,Wenfang Peng,Shan Huang
Gene. 2020; 758: 144952
[Pubmed] | [DOI]
57 Web-based tools for miRNA studies analysis
Fatemeh Shaker,Abbas Nikravesh,Roghaye Arezumand,Seyed Hamid Aghaee-Bakhtiari
Computers in Biology and Medicine. 2020; 127: 104060
[Pubmed] | [DOI]
58 MicroRNA -206 inhibits influenza A virus replication by targeting tankyrase 2
Gayan Bamunuarachchi,Xiaoyun Yang,Chaoqun Huang,Yurong Liang,Yujie Guo,Lin Liu
Cellular Microbiology. 2020;
[Pubmed] | [DOI]
59 DNA Strands Trigger the Intracellular Release of Drugs from Mucin-Based Nanocarriers
Ceren Kimna,Theresa Monika Lutz,Hongji Yan,Jian Song,Thomas Crouzier,Oliver Lieleg
ACS Nano. 2020;
[Pubmed] | [DOI]
60 miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia
Thi Thanh Vu,Friedrich Stölzel,Kristy W. Wang,Christoph Röllig,Melinda L. Tursky,Timothy J. Molloy,David D. Ma
Leukemia. 2020;
[Pubmed] | [DOI]
61 MicroRNA-1 Modulates Chondrocyte Phenotype by Regulating FZD7 of Wnt/ß-Catenin Signaling Pathway
Yang Yang, Yawei Wang, Haobo Jia, Bing Li, Dan Xing, Jiao Jiao Li
CARTILAGE. 2020; : 1947603520
[Pubmed] | [DOI]
62 Differential MicroRNA-Signatures in Thyroid Cancer Subtypes
Krystal Santiago,Yan Chen Wongworawat,Salma Khan
Journal of Oncology. 2020; 2020: 1
[Pubmed] | [DOI]
63 Small Extracellular Vesicles from Human Fetal Dermal Cells and Their MicroRNA Cargo: KEGG Signaling Pathways Associated with Angiogenesis and Wound Healing
Cinzia Maria Chinnici,Giandomenico Amico,Alessia Gallo,Gioacchin Iannolo,Nicola Cuscino,Serena Vella,Claudia Carcione,David Nascari,Pier Giulio Conaldi
Stem Cells International. 2020; 2020: 1
[Pubmed] | [DOI]
64 Pseudogene-gene functional networks are prognostic of patient survival in breast cancer
Sasha Smerekanych,Travis S. Johnson,Kun Huang,Yan Zhang
BMC Medical Genomics. 2020; 13(S5)
[Pubmed] | [DOI]
65 iDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding
Huiyuan Chen,Feixiong Cheng,Jing Li,Avner Schlessinger
PLOS Computational Biology. 2020; 16(7): e1008040
[Pubmed] | [DOI]
66 Regulation of hepatic microRNAs in response to early stage Echinococcus multilocularis egg infection in C57BL/6 mice
Ghalia Boubaker,Sebastian Strempel,Andrew Hemphill,Norbert Müller,Junhua Wang,Bruno Gottstein,Markus Spiliotis,Gabriel Rinaldi
PLOS Neglected Tropical Diseases. 2020; 14(5): e0007640
[Pubmed] | [DOI]
67 Otoimmün tiroid hastaliklarinda CTLA-4 geninin in silico analizinin degerlendirilmesi
Duygu KIRKIK,Sevgi KALKANLI,Eylem ÇAGILTAY,Nevin KALKANLI
Journal of Medicine and Palliative Care. 2020;
[Pubmed] | [DOI]
68 Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs
Douâa Moussa Agha,Redouane Rouas,Mehdi Najar,Fatima Bouhtit,Najib Naamane,Hussein Fayyad-Kazan,Dominique Bron,Nathalie Meuleman,Philippe Lewalle,Makram Merimi
International Journal of Molecular Sciences. 2020; 21(19): 7065
[Pubmed] | [DOI]
69 Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
Marcus Bauer,Christoforos Vaxevanis,Nadine Heimer,Haifa Kathrin Al-Ali,Nadja Jaekel,Michael Bachmann,Claudia Wickenhauser,Barbara Seliger
International Journal of Molecular Sciences. 2020; 21(19): 7140
[Pubmed] | [DOI]
70 MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
Noor Altaleb
Clinical Cancer Drugs. 2020; 7(2): 65
[Pubmed] | [DOI]
71 Epigenetic Marks in Polycystic Ovary Syndrome
Alicia Beatriz Motta
Current Medicinal Chemistry. 2020; 27(39): 6727
[Pubmed] | [DOI]
72 Mesenchymal Stem Cell and MicroRNA Therapy of Musculoskeletal Diseases
Myung-Jin Chung,Ji-Yoon Son,SunYoung Park,Soon-Seok Park,Keun Hur,Sang-Han Lee,Eun-Joo Lee,Jin-Kyu Park,Il-Hwa Hong,Tae-Hwan Kim,Kyu-Shik Jeong
International Journal of Stem Cells. 2020;
[Pubmed] | [DOI]
73 Tick Salivary Compounds for Targeted Immunomodulatory Therapy
Hajer Aounallah,Chaima Bensaoud,Youmna M’ghirbi,Fernanda Faria,Jindr?ich Chmelar?,Michail Kotsyfakis
Frontiers in Immunology. 2020; 11
[Pubmed] | [DOI]
74 Editorial: Regulation of Soluble Immune Mediators by Non-Coding RNAs
Daniela Bosisio,Flavia Bazzoni
Frontiers in Immunology. 2020; 11
[Pubmed] | [DOI]
75 Small-Medium Extracellular Vesicles and Their miRNA Cargo in Retinal Health and Degeneration: Mediators of Homeostasis, and Vehicles for Targeted Gene Therapy
Yvette Wooff,Adrian V. Cioanca,Joshua A. Chu-Tan,Riemke Aggio-Bruce,Ulrike Schumann,Riccardo Natoli
Frontiers in Cellular Neuroscience. 2020; 14
[Pubmed] | [DOI]
76 microRNA-137 downregulates MCL1 in ovarian cancer cells and mediates cisplatin-induced apoptosis
Wei Chen,Jingjie Du,Xiaodi Li,Ziming Zhi,Songshan Jiang
Pharmacogenomics. 2020; 21(3): 195
[Pubmed] | [DOI]
77 The roles of miRNAs’ clinical efficiencies in the colorectal cancer pathobiology: A review article
Nahal Eshghifar,Elham Badrlou,Farkhondeh Pouresmaeili
Human Antibodies. 2020; 28(4): 273
[Pubmed] | [DOI]
78 Epigenetic regulation by polyphenols in diabetes and related complications
Hammad Ullah,Anna De Filippis,Cristina Santarcangelo,Maria Daglia
Mediterranean Journal of Nutrition and Metabolism. 2020; : 1
[Pubmed] | [DOI]
79 Let-7i-5p Regulation of Cell Morphology and Migration Through Distinct Signaling Pathways in Normal and Pathogenic Urethral Fibroblasts
Kaile Zhang,Ranxin Yang,Jun Chen,Er Qi,Shukui Zhou,Ying Wang,Qiang Fu,Rong Chen,Xiaolan Fang
Frontiers in Bioengineering and Biotechnology. 2020; 8
[Pubmed] | [DOI]
80 The Enigmatic Role of Serum & Glucocorticoid Inducible Kinase 1 in the Endometrium
Florian Lang,Janet Rajaxavier,Yogesh Singh,Sara Y. Brucker,Madhuri S. Salker
Frontiers in Cell and Developmental Biology. 2020; 8
[Pubmed] | [DOI]
81 Structural Insights on Tiny Peptide Nucleic Acid (PNA) Analogues of miRNA-34a: An in silico and Experimental Integrated Approach
Maria Moccia,Flavia Anna Mercurio,Emma Langella,Valerio Piacenti,Marilisa Leone,Mauro F. A. Adamo,Michele Saviano
Frontiers in Chemistry. 2020; 8
[Pubmed] | [DOI]
82 snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management
Nour-El-Houda Mourksi,Chloé Morin,Tanguy Fenouil,Jean-Jacques Diaz,Virginie Marcel
Cells. 2020; 9(3): 541
[Pubmed] | [DOI]
83 The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
Simoneide S. Titze-de-Almeida,Cristina Soto-Sánchez,Eduardo Fernandez,James B. Koprich,Jonathan M. Brotchie,Ricardo Titze-de-Almeida
Cells. 2020; 9(4): 841
[Pubmed] | [DOI]
84 MiR-337-3p Promotes Adipocyte Browning by Inhibiting TWIST1
Indira G.C. Vonhögen,Hamid el Azzouzi,Servé Olieslagers,Aliaksei Vasilevich,Jan de Boer,Francisco J. Tinahones,Paula A. da Costa Martins,Leon J. de Windt,Mora Murri
Cells. 2020; 9(4): 1056
[Pubmed] | [DOI]
85 miR-615 Fine-Tunes Growth and Development and Has a Role in Cancer and in Neural Repair
Marisol Godínez-Rubí,Daniel Ortuño-Sahagún
Cells. 2020; 9(7): 1566
[Pubmed] | [DOI]
86 miR-7 Regulates GLP-1-Mediated Insulin Release by Targeting ß-Arrestin 1
Alessandro Matarese,Jessica Gambardella,Angela Lombardi,Xujun Wang,Gaetano Santulli
Cells. 2020; 9(7): 1621
[Pubmed] | [DOI]
87 MicroRNA Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton
Karen Uray,Evelin Major,Beata Lontay
Cells. 2020; 9(7): 1649
[Pubmed] | [DOI]
88 Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders
Sujay Paul,Luis Alberto Bravo Vázquez,Samantha Pérez Uribe,Paula Roxana Reyes-Pérez,Ashutosh Sharma
Cells. 2020; 9(7): 1698
[Pubmed] | [DOI]
89 miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children
Michela Visani,Gianluca Marucci,Dario de Biase,Felice Giangaspero,Francesca Romana Buttarelli,Alba Ariela Brandes,Enrico Franceschi,Giorgia Acquaviva,Alessia Ciarrocchi,Kerry Jane Rhoden,Giovanni Tallini,Annalisa Pession
Diagnostics. 2020; 10(5): 265
[Pubmed] | [DOI]
90 Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions
Abbas Jarrahi,Molly Braun,Meenakshi Ahluwalia,Rohan V. Gupta,Michael Wilson,Stephanie Munie,Pankaj Ahluwalia,John R. Vender,Fernando L. Vale,Krishnan M. Dhandapani,Kumar Vaibhav
Biomedicines. 2020; 8(10): 389
[Pubmed] | [DOI]
91 miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19
Alessandro Matarese,Jessica Gambardella,Celestino Sardu,Gaetano Santulli
Biomedicines. 2020; 8(11): 462
[Pubmed] | [DOI]
92 Up-regulation of MicroRNAs-21 and -223 in a Sprague-Dawley Rat Model of Traumatic Spinal Cord Injury
Hyo-Jin Chung,Wook-Hun Chung,Sun-Hee Do,Jae-Hoon Lee,Hwi-yool Kim
Brain Sciences. 2020; 10(3): 141
[Pubmed] | [DOI]
93 MicroRNAs in Rectal Cancer: Functional Significance and Promising Therapeutic Value
Laura Imedio,Ion Cristóbal,Jaime Rubio,Andrea Santos,Federico Rojo,Jesús García-Foncillas
Cancers. 2020; 12(8): 2040
[Pubmed] | [DOI]
94 miR-146a-5p and miR-193a-5p Synergistically Inhibited the Proliferation of Human Colorectal Cancer Cells (HT-29 cell line) through ERK Signaling Pathway
Saeed Noorolyai,Elham Baghbani,Dariush Shanehbandi,Vahid Khaze Shahgoli,Amir Baghbanzadeh Kojabad,Behzad Mansoori,Khalil Hajiasgharzadeh,Ahad Mokhtarzadeh,Behzad Baradaran
Advanced Pharmaceutical Bulletin. 2020; 11(4): 755
[Pubmed] | [DOI]
95 Differentially Expressed microRNAs in MIA PaCa-2 and PANC-1 Pancreas Ductal Adenocarcinoma Cell Lines are Involved in Cancer Stem Cell Regulation
JenaJ Shen,JenaJ Pu,JenaJ Zheng,JenaJ Ma,JenaJ Qin,JenaJ Jiang,JenaJ Li
International Journal of Molecular Sciences. 2019; 20(18): 4473
[Pubmed] | [DOI]
96 RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
Armin Zebisch,Veronica Caraffini,Heinz Sill
International Journal of Molecular Sciences. 2019; 20(22): 5756
[Pubmed] | [DOI]
97 A Brief Overview of lncRNAs in Endothelial Dysfunction-Associated Diseases: From Discovery to Characterization
Rashidul Islam,Christopher Lai
Epigenomes. 2019; 3(3): 20
[Pubmed] | [DOI]
98 Novel Treatments for Polycystic Kidney Disease
Ameya Patil,William E. Sweeney,Cynthia G. Pan,Ellis D. Avner,Meral Gunay-Aygun
Translational Science of Rare Diseases. 2019; 4(1-2): 77
[Pubmed] | [DOI]
99 Cytokine Targeting by miRNAs in Autoimmune Diseases
Valentina Salvi,Veronica Gianello,Laura Tiberio,Silvano Sozzani,Daniela Bosisio
Frontiers in Immunology. 2019; 10
[Pubmed] | [DOI]
100 Application of microRNA in the therapy of ischemic stroke
I. F. Gareev,L. B. Novikova,O. A. Beylerli
Cardiovascular Therapy and Prevention. 2019; 18(5): 66
[Pubmed] | [DOI]
101 Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-a)
Sagarika Biswas
Current Drug Therapy. 2019; 14(1): 85
[Pubmed] | [DOI]
102 Screening of microRNAs controlling body fat in Drosophila melanogaster and identification of miR-969 and its target, Gr47b
William Redmond,Dylan Allen,M. Christian Elledge,Russell Arellanes,Lucille Redmond,Jared Yeahquo,Shuyin Zhang,Morgan Youngblood,Austin Reiner,Jin Seo,Gregg Roman
PLOS ONE. 2019; 14(7): e0219707
[Pubmed] | [DOI]
103 Demonstrating specificity of bioactive peptide nucleic acids (PNAs) targeting microRNAs for practical laboratory classes of applied biochemistry and pharmacology
Jessica Gasparello,Chiara Papi,Matteo Zurlo,Roberto Corradini,Roberto Gambari,Alessia Finotti,Maxim Antopolsky
PLOS ONE. 2019; 14(9): e0221923
[Pubmed] | [DOI]
104 miR-181a/b downregulation exerts a protective action on mitochondrial disease models
Alessia Indrieri,Sabrina Carrella,Alessia Romano,Alessandra Spaziano,Elena Marrocco,Erika Fernandez-Vizarra,Sara Barbato,Mariateresa Pizzo,Yulia Ezhova,Francesca M Golia,Ludovica Ciampi,Roberta Tammaro,Jorge Henao-Mejia,Adam Williams,Richard A Flavell,Elvira De Leonibus,Massimo Zeviani,Enrico M Surace,Sandro Banfi,Brunella Franco
EMBO Molecular Medicine. 2019; 11(5)
[Pubmed] | [DOI]
105 miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?
A K M Nawshad Hossian,Gerardo G Mackenzie,George Mattheolabakis
Nanomedicine. 2019;
[Pubmed] | [DOI]
106 Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology
Jianjun Lu,Wei Zhang,Yang Ding,Xiang Li,Jiandong Song
Oncology Letters. 2019;
[Pubmed] | [DOI]
107 Improved annotation of Lutzomyia longipalpis genome using bioinformatics analysis
Zhiyuan Yang,Ying Wu
PeerJ. 2019; 7: e7862
[Pubmed] | [DOI]
108 Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs
Daria Skuratovskaia,Maria Vulf,Aleksandra Komar,Elena Kirienkova,Larisa Litvinova
Biomolecules. 2019; 9(6): 226
[Pubmed] | [DOI]
109 Applications of miRNAs in cardiac development, disease progression and regeneration
Jeremy Kah Sheng Pang,Qian Hua Phua,Boon-Seng Soh
Stem Cell Research & Therapy. 2019; 10(1)
[Pubmed] | [DOI]
110 The therapeutic effects of microRNAs in preclinical studies of acute kidney injury: a systematic review protocol
Sarah Zankar,Rosendo A. Rodriguez,Jose Luis Vinas,Kevin D. Burns
Systematic Reviews. 2019; 8(1)
[Pubmed] | [DOI]
111 Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells
Olga D’Almeida,Omar Mothar,Esther Apraku Bondzie,Yolande Lieumo,Laure Tagne,Sumeet Gupta,Thomas Volkert,Stuart Levine,Jean-Bosco Tagne
BMC Cancer. 2019; 19(1)
[Pubmed] | [DOI]
112 A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing ß5-integrin/c-met signaling pathway
Wei-Chieh Huang,Te-Hsuan Jang,Shiao-Lin Tung,Tzu-Chen Yen,Shih-Hsuan Chan,Lu-Hai Wang
Journal of Experimental & Clinical Cancer Research. 2019; 38(1)
[Pubmed] | [DOI]
113 Adipokines Regulate the Expression of Tumor-Relevant MicroRNAs
Simon Jasinski-Bergner, Heike Kielstein
Obesity Facts. 2019; 12(2): 211
[Pubmed] | [DOI]
114 Abnormal Expression of miR-21 in Kidney Tissue of Dogs With X-Linked Hereditary Nephropathy: A Canine Model of Chronic Kidney Disease
Sabrina D. Clark,Wenping Song,Rachel Cianciolo,George Lees,Mary Nabity,Shiguang Liu
Veterinary Pathology. 2019; 56(1): 93
[Pubmed] | [DOI]
115 Inhibition of microRNA-711 limits angiopoietin-1 and Akt changes, tissue damage, and motor dysfunction after contusive spinal cord injury in mice
Boris Sabirzhanov,Jessica Matyas,Marina Coll-Miro,Laina Lijia Yu,Alan I. Faden,Bogdan A. Stoica,Junfang Wu
Cell Death & Disease. 2019; 10(11)
[Pubmed] | [DOI]
116 Adipocyte metabolism is improved by TNF receptor-targeting small RNAs identified from dried nuts
Katia Aquilano,Veronica Ceci,Angelo Gismondi,Susanna De Stefano,Federico Iacovelli,Raffaella Faraonio,Gabriele Di Marco,Noemi Poerio,Antonella Minutolo,Giuseppina Minopoli,Antonia Marcone,Maurizio Fraziano,Flavia Tortolici,Simona Sennato,Stefano Casciardi,Marina Potestà,Roberta Bernardini,Maurizio Mattei,Mattia Falconi,Carla Montesano,Stefano Rufini,Antonella Canini,Daniele Lettieri-Barbato
Communications Biology. 2019; 2(1)
[Pubmed] | [DOI]
117 MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of haem oxygenase-1 expression
Wei-Chun Chen,Chih-Ku Wei,Jin-Ching Lee
Journal of Viral Hepatitis. 2019;
[Pubmed] | [DOI]
118 Transcriptomic studies provide insights into the tumor suppressive role of miR-146a-5p in non-small cell lung cancer (NSCLC) cells
Joseph R. Iacona,Nicholas J. Monteleone,Alexander D. Lemenze,Ashley L. Cornett,Carol S. Lutz
RNA Biology. 2019; : 1
[Pubmed] | [DOI]
119 The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases
Luca Antonioli,Corrado Blandizzi,Pál Pacher,György Haskó,Clive Page
Pharmacological Reviews. 2019; 71(3): 345
[Pubmed] | [DOI]
120 Molecular mechanism of miR-204 regulates proliferation, apoptosis and autophagy of cervical cancer cells by targeting ATF2
Nan Li,XiaoRong Guo,Lei Liu,Lu Wang,Rongjie Cheng
Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47(1): 2529
[Pubmed] | [DOI]
121 Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome
Jifan Guo,Wenping Song,Joseph Boulanger,Ethan Y. Xu,Fang Wang,Yanqin Zhang,Qun He,Suxia Wang,Li Yang,Cynthia Pryce,Lucy Phillips,Deidre MacKenna,Ekkehard Leberer,Oxana Ibraghimov-Beskrovnaya,Jie Ding,Shiguang Liu
Human Gene Therapy. 2019;
[Pubmed] | [DOI]
122 Pathogenesis and treatment of autoimmune rheumatic diseases
Eric Liu,Andras Perl
Current Opinion in Rheumatology. 2019; 31(3): 307
[Pubmed] | [DOI]
123 miR-146a targeted to splenic macrophages prevents sepsis-induced multiple organ injury
Yoshio Funahashi,Noritoshi Kato,Tomohiro Masuda,Fumitoshi Nishio,Hiroki Kitai,Takuji Ishimoto,Tomoki Kosugi,Naotake Tsuboi,Naoyuki Matsuda,Shoichi Maruyama,Kenji Kadomatsu
Laboratory Investigation. 2019;
[Pubmed] | [DOI]
124 MicroRNA-519d-3p inhibits cell proliferation and cell cycle G1/S transition in glioma by targeting CCND1
Lishan Ma,Jin Li
Bioscience, Biotechnology, and Biochemistry. 2019; : 1
[Pubmed] | [DOI]
125 A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles
Christine Vauthier
Journal of Drug Targeting. 2019; : 1
[Pubmed] | [DOI]
126 Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview
Eliane Piket,Galina Yurevna Zheleznyakova,Lara Kular,Maja Jagodic
Journal of Autoimmunity. 2019;
[Pubmed] | [DOI]
127 Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma
Rebecca Kohnken,Betina McNeil,Jing Wen,Kathleen McConnell,Leah Grinshpun,Ashleigh Keiter,Luxi Chen,Basem William,Pierluigi Porcu,Anjali Mishra
Journal of Investigative Dermatology. 2019;
[Pubmed] | [DOI]
128 Diabetic Nephropathy: the regulatory interplay between Epigenetics and microRNAs
Himanshu Sankrityayan,Yogesh A. Kulkarni,Anil Bhanudas Gaikwad
Pharmacological Research. 2019;
[Pubmed] | [DOI]
129 Regulación por micro RNA de la respuesta angiogénica en la retina diabética
Helena Cristina Campos-Borges,Silvia María Sanz-González,Vicente Zanón-Moreno,Jose María Millán Salvador,María Dolores Pinazo-Duran
Archivos de la Sociedad Española de Oftalmología. 2019;
[Pubmed] | [DOI]
130 Micro-RNA regulation of the angiogenic response in the diabetic retina
H.C. Campos-Borges,S.M. Sanz-González,V. Zanón-Moreno,J.M. Millán Salvador,M.D. Pinazo-Duran
Archivos de la Sociedad Española de Oftalmología (English Edition). 2019;
[Pubmed] | [DOI]
131 A Sendai Virus-Based Cytoplasmic RNA Vector as a Novel Platform for Long-Term Expression of MicroRNAs
Masayuki Sano,Asako Nakasu,Manami Ohtaka,Mahito Nakanishi
Molecular Therapy - Methods & Clinical Development. 2019; 15: 371
[Pubmed] | [DOI]
132 Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle
Jessica Gasparello,Michela Lomazzi,Chiara Papi,Elisabetta D’Aversa,Francesco Sansone,Alessandro Casnati,Gaetano Donofrio,Roberto Gambari,Alessia Finotti
Molecular Therapy - Nucleic Acids. 2019; 18: 748
[Pubmed] | [DOI]
133 Efferocytosis and Atherosclerosis: Regulation of Phagocyte Function by MicroRNAs
Amir Tajbakhsh,Vanessa Bianconi,Matteo Pirro,Seyed Mohammad Gheibi Hayat,Thomas P. Johnston,Amirhossein Sahebkar
Trends in Endocrinology & Metabolism. 2019;
[Pubmed] | [DOI]
134 PATHOGENIC IMPLICATIONS OF DYSREGULATED miRNAs IN PROPIONIC ACIDEMIA RELATED CARDIOMYOPATHY
Alejandro Fulgencio-Covián,Esmeralda Alonso-Barroso,Adam J Guenzel,Ana Rivera-Barahona,Magdalena Ugarte,Belén Pérez,Michael A Barry,Celia Pérez-Cerdá,Eva Richard,Lourdes R Desviat
Translational Research. 2019;
[Pubmed] | [DOI]
135 miRNAs and their roles in KSHV pathogenesis
Hosni A.M. Hussein,Mohammad A. Alfhili,Pranaya Pakala,Sandra Simon,Jaffer Hussain,James A. McCubrey,Shaw M. Akula
Virus Research. 2019; 266: 15
[Pubmed] | [DOI]
136 Therapeutic microRNAs in human cancer
Gizem Ors-Kumoglu,Sultan Gulce-Iz,Cigir Biray-Avci
Cytotechnology. 2019;
[Pubmed] | [DOI]
137 A cross-cancer metastasis signature in the microRNA–mRNA axis of paired tissue samples
Samuel C. Lee,Alistair Quinn,Thin Nguyen,Svetha Venkatesh,Thomas P. Quinn
Molecular Biology Reports. 2019;
[Pubmed] | [DOI]
138 Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment
Parisa Gazerani
Molecular Diagnosis & Therapy. 2019;
[Pubmed] | [DOI]
139 Early-onset preeclampsia, plasma microRNAs, and endothelial cell function
Simone V. Lip,Mark V. Boekschoten,Guido J. Hooiveld,Mariëlle G. van Pampus,Sicco A. Scherjon,Torsten Plösch,Marijke M. Faas
American Journal of Obstetrics and Gynecology. 2019;
[Pubmed] | [DOI]
140 Developmental origins of type 2 diabetes: Focus on epigenetics
Alexander Vaiserman,Oleh Lushchak
Ageing Research Reviews. 2019; 55: 100957
[Pubmed] | [DOI]
141 MicroRNA-193a and taxol combination: A new strategy for treatment of colorectal cancer
Maryam Hejazi,Elham Baghbani,Mohammad Amini,Tayebeh Rezaei,Ayuob Aghanejad,Jafar Mosafer,Ahad Mokhtarzadeh,Behzad Baradaran
Journal of Cellular Biochemistry. 2019;
[Pubmed] | [DOI]
142 miR-146b Reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells
Qian Han,Peng Cheng,Hongjie Yang,Hengpo Liang,Fengchun Lin
Journal of Cellular Biochemistry. 2019;
[Pubmed] | [DOI]
143 miR-146a-5p: Expression, regulation, and functions in cancer
Joseph R. Iacona,Carol S. Lutz
Wiley Interdisciplinary Reviews: RNA. 2019; : e1533
[Pubmed] | [DOI]
144 Dgcr8 knockout approaches to understand microRNA functions in vitro and in vivo
Wen-Ting Guo,Yangming Wang
Cellular and Molecular Life Sciences. 2019;
[Pubmed] | [DOI]
145 The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target
Golamreza Jadideslam,Khalil Ansarin,Ebrahim Sakhinia,Shahriar Alipour,Farhad Pouremamali,Alireza Khabbazi
Journal of Cellular Physiology. 2018;
[Pubmed] | [DOI]
146 miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Marcin Serocki,Sylwia Bartoszewska,Anna Janaszak-Jasiecka,Renata J. Ochocka,James F. Collawn,Rafal Bartoszewski
Angiogenesis. 2018;
[Pubmed] | [DOI]
147 miR-30a-5p inhibition promotes interaction of Fas+ endothelial cells and FasL+ microglia to decrease pathological neovascularization and promote physiological angiogenesis
Salome Murinello,Yoshihiko Usui,Susumu Sakimoto,Maki Kitano,Edith Aguilar,H. Maura Friedlander,Amelia Schricker,Carli Wittgrove,Yoshihiro Wakabayashi,Michael I. Dorrell,Peter D. Westenskow,Martin Friedlander
Glia. 2018;
[Pubmed] | [DOI]
148 MicroRNA-124 and microRNA-146a both attenuate persistent neuropathic pain induced by morphine in male rats
Peter M. Grace,Keith A. Strand,Erika L. Galer,Steven F. Maier,Linda R. Watkins
Brain Research. 2018; 1692: 9
[Pubmed] | [DOI]
149 Perspectives on the physiological roles of microRNAs in immune-metabolism: Where are we now?
Shuai Jiang
Cancer Letters. 2018; 426: 1
[Pubmed] | [DOI]
150 An innovative paradigm of methods in microRNAs detection: highlighting DNAzymes, the illuminators
Mojdeh Mahdiannasser,Zahra Karami
Biosensors and Bioelectronics. 2018; 107: 123
[Pubmed] | [DOI]
151 Biomarkers in Spinal Cord Injury: from Prognosis to Treatment
Leonardo Fonseca Rodrigues,Vivaldo Moura-Neto,Tania Cristina Leite de Sampaio e Spohr
Molecular Neurobiology. 2018;
[Pubmed] | [DOI]
152 Calcium-Binding Nanoparticles for Vascular Disease
Deborah D. Chin,Sampreeti Chowdhuri,Eun Ji Chung
Regenerative Engineering and Translational Medicine. 2018;
[Pubmed] | [DOI]
153 A physiologically relevant 3D collagen-based scaffold–neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models
C. Curtin,J.C. Nolan,R. Conlon,L. Deneweth,C. Gallagher,Y.J. Tan,B.L. Cavanagh,A.Z. Asraf,H. Harvey,S. Miller-Delaney,J. Shohet,I. Bray,F.J. OæBrien,R.L. Stallings,O. Piskareva
Acta Biomaterialia. 2018;
[Pubmed] | [DOI]
154 Emerging ways to treat breast cancer: will promises be met?
Pouria Samadi,Sahar Saki,Fatemeh Karimi Dermani,Mona Pourjafar,Massoud Saidijam
Cellular Oncology. 2018;
[Pubmed] | [DOI]
155 Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses
Duo Zhang,Heedoo Lee,Xiaoyun Wang,Ashish Rai,Michael Groot,Yang Jin
Molecular Therapy. 2018;
[Pubmed] | [DOI]
156 At the heart of programming: the role of micro-RNAs
B. Siddeek,C. Mauduit,C. Yzydorczyk,M. Benahmed,U. Simeoni
Journal of Developmental Origins of Health and Disease. 2018; : 1
[Pubmed] | [DOI]
157 Combined Therapy in Cancer: The Non-coding Approach
Diana Gulei,Ioana Berindan-Neagoe
Molecular Therapy - Nucleic Acids. 2018; 12: 787
[Pubmed] | [DOI]
158 Multifunctional nanocarrier as a potential micro-RNA delivery vehicle for neuroblastoma treatment
Ndumiso Vukile Mdlovu,Yun Chen,Kuen-Song Lin,Ming-Wei Hsu,Steven S.-S. Wang,Chun-Ming Wu,You-Sheng Lin,Kazuki Ohishi
Journal of the Taiwan Institute of Chemical Engineers. 2018;
[Pubmed] | [DOI]
159 Reproductive role of miRNA in the hypothalamic-pituitary axis
Chunyu Cao,Yifei Ding,Xiangjun Kong,Guangde Feng,Wei Xiang,Long Chen,Fang Yang,Ke Zhang,Mingxing Chu,Pingqing Wang,Baoyun Zhang
Molecular and Cellular Neuroscience. 2018; 88: 130
[Pubmed] | [DOI]
160 Expression Analysis of microRNA-21 and microRNA-122 in Hepatocellular Carcinoma
Dipu Bharali,Basu Dev Banerjee,Mausumi Bharadwaj,Syed Akhtar Husain,Premashis Kar
Journal of Clinical and Experimental Hepatology. 2018;
[Pubmed] | [DOI]
161 Therapeutic applications of zebrafish (Danio rerio) miRNAs linked with human diseases: A prospective review
Manojit Bhattacharya,Soumendu Ghosh,Ramesh Chandra Malick,Bidhan Chandra Patra,Basanta Kumar Das
Gene. 2018; 679: 202
[Pubmed] | [DOI]
162 Epigenetic Changes in Airway Smooth Muscle as a Driver of Airway Inflammation and Remodeling in Asthma
Klaudia A. Kaczmarek,Rachel L. Clifford,Alan J. Knox
Chest. 2018;
[Pubmed] | [DOI]
163 Analysis of microRNA and modified oligonucleotides with the use of ultra high performance liquid chromatography coupled with mass spectrometry
Sylwia Studzinska,Boguslaw Buszewski
Journal of Chromatography A. 2018;
[Pubmed] | [DOI]
164 Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn’s disease
Nóra Judit Béres,Zoltán Kiss,Katalin E. Müller,Áron Cseh,Apor Veres-Székely,Rita Lippai,Rita Benko,Árpád Bartha,Szabolcs Heininger,Ádám Vannay,Erna Sziksz,Gábor Veres,Eszter M. Horváth
Scandinavian Journal of Gastroenterology. 2018; : 1
[Pubmed] | [DOI]
165 New insights into the genetics and epigenetics of systemic sclerosis
Chiara Angiolilli,Wioleta Marut,Maarten van der Kroef,Eleni Chouri,Kris A. Reedquist,Timothy R. D. J. Radstake
Nature Reviews Rheumatology. 2018;
[Pubmed] | [DOI]
166 TGF-ß induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Silvia Ottaviani,Justin Stebbing,Adam E. Frampton,Sladjana Zagorac,Jonathan Krell,Alexander de Giorgio,Sara M. Trabulo,Van T. M. Nguyen,Luca Magnani,Hugang Feng,Elisa Giovannetti,Niccola Funel,Thomas M. Gress,Long R. Jiao,Ylenia Lombardo,Nicholas R. Lemoine,Christopher Heeschen,Leandro Castellano
Nature Communications. 2018; 9(1)
[Pubmed] | [DOI]
167 Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells
Ingrid Fomison-Nurse,Eugene Eng Leng Saw,Sophie Gandhi,Pujika Emani Munasinghe,Isabelle Van Hout,Michael J. A Williams,Ivor Galvin,Richard Bunton,Philip Davis,Vicky Cameron,Rajesh Katare
Cell Death & Differentiation. 2018;
[Pubmed] | [DOI]
168 The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression
Diana Gulei,Lorand Magdo,Ancuta Jurj,Lajos Raduly,Roxana Cojocneanu-Petric,Alin Moldovan,Cristian Moldovan,Adrian Florea,Sergiu Pasca,Laura-Ancuta Pop,Vlad Moisoiu,Liviuta Budisan,Cecilia Pop-Bica,Cristina Ciocan,Rares Buiga,Mihai-Stefan Muresan,Rares Stiufiuc,Calin Ionescu,Ioana Berindan-Neagoe
Cell Death & Disease. 2018; 9(2)
[Pubmed] | [DOI]
169 PTBP1 enhances miR-101-guided AGO2 targeting to MCL1 and promotes miR-101-induced apoptosis
Jia Cui,William J. Placzek
Cell Death & Disease. 2018; 9(5)
[Pubmed] | [DOI]
170 MicroRNAs: Roles in Regulating Neuroinflammation
Andrew D. Gaudet,Laura K. Fonken,Linda R. Watkins,Randy J. Nelson,Phillip G. Popovich
The Neuroscientist. 2018; 24(3): 221
[Pubmed] | [DOI]
171 MicroRNA-based therapeutics in central nervous system injuries
Ping Sun,Da Zhi Liu,Glen C Jickling,Frank R Sharp,Ke-Jie Yin
Journal of Cerebral Blood Flow & Metabolism. 2018; 38(7): 1125
[Pubmed] | [DOI]
172 miRTissue: a web application for the analysis of miRNA-target interactions in human tissues
Antonino Fiannaca,Massimo La Rosa,Laura La Paglia,Alfonso Urso
BMC Bioinformatics. 2018; 19(S15)
[Pubmed] | [DOI]
173 Predictive modeling of miRNA-mediated predisposition to alcohol-related phenotypes in mouse
Pratyaydipta Rudra,Wen J. Shi,Pamela Russell,Brian Vestal,Boris Tabakoff,Paula Hoffman,Katerina Kechris,Laura Saba
BMC Genomics. 2018; 19(1)
[Pubmed] | [DOI]
174 Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
Mi Ran Yun,Sun Min Lim,Seon-Kyu Kim,Hun Mi Choi,Kyoung-Ho Pyo,Seong Keun Kim,Ji Min Lee,You Won Lee,Jae Woo Choi,Hye Ryun Kim,Min Hee Hong,Keeok Haam,Nanhyung Huh,Jong-Hwan Kim,Yong Sung Kim,Hyo Sup Shim,Ross Andrew Soo,Jin-Yuan Shih,James Chih-Hsin Yang,Mirang Kim,Byoung Chul Cho
Cancer Research. 2018; 78(12): 3350
[Pubmed] | [DOI]
175 Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone
Alyson A. Fiorillo,Christopher B. Tully,Jesse M. Damsker,Kanneboyina Nagaraju,Eric P. Hoffman,Christopher R. Heier
Physiological Genomics. 2018; 50(9): 735
[Pubmed] | [DOI]
176 Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)
Jessica Gasparello,Matteo Allegretti,Elisa Tremante,Enrica Fabbri,Carla Azzurra Amoreo,Paolo Romania,Elisa Melucci,Katia Messana,Monica Borgatti,Patrizio Giacomini,Roberto Gambari,Alessia Finotti
Journal of Experimental & Clinical Cancer Research. 2018; 37(1)
[Pubmed] | [DOI]
177 MicroRNAs regulate survival in oxygen-deprived environments
Simon G. English,Hanane Hadj-Moussa,Kenneth B. Storey
The Journal of Experimental Biology. 2018; 221(23): jeb190579
[Pubmed] | [DOI]
178 Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives
Rosa Hernández,Ester Sánchez-Jiménez,Consolación Melguizo,Jose Prados,Ana Rosa Rama
BMB Reports. 2018; 51(11): 563
[Pubmed] | [DOI]
179 Unique interstitial miRNA signature drives fibrosis in a murine model of autosomal dominant polycystic kidney disease
Ameya Patil,William E Sweeney Jr,Cynthia G Pan,Ellis D Avner
World Journal of Nephrology. 2018; 7(5): 108
[Pubmed] | [DOI]
180 miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer
Pavol Zubor,Peter Kubatka,Zuzana Dankova,Alexandra Gondova,Karol Kajo,Jozef Hatok,Marek Samec,Marianna Jagelkova,Stefan Krivus,Veronika Holubekova,Jan Bujnak,Zuzana Laucekova,Katarina Zelinova,Igor Stastny,Marcela Nachajova,Jan Danko,Olga Golubnitschaja
Future Oncology. 2018;
[Pubmed] | [DOI]
181 MicroRNA expression in melanocytes and melanoma cells
A. A. Petkevich,I. Sh. Shubina,A. A. Abramov,L. T. Mamedova,I. V. Samoilenko,M. V. Kiselevsky
Russian Journal of Biotherapy. 2018; 17(3): 6
[Pubmed] | [DOI]
182 Pentafluoropropionic Anhydride Functionalized PAMAM Dendrimer as miRNA Delivery Reagent
Ali Oztuna,Hasan Nazir
Journal of the Turkish Chemical Society, Section A: Chemistry. 2018; : 1295
[Pubmed] | [DOI]
183 Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis
Ji Suk Kim,Kyoungjune Pak,Tae Sik Goh,Dae Cheon Jeong,Myoung-Eun Han,Jihyun Kim,Sae-Ock Oh,Chi Dae Kim,Yun Hak Kim
Yonsei Medical Journal. 2018; 59(4): 495
[Pubmed] | [DOI]
184 Temporal Integrative Analysis of mRNA and microRNAs Expression Profiles and Epigenetic Alterations in Female SAMP8, a Model of Age-Related Cognitive Decline
Marta Cosín-Tomás,María Jesús Álvarez-López,Júlia Companys-Alemany,Perla Kaliman,Celia González-Castillo,Daniel Ortuño-Sahagún,Mercè Pallàs,Christian Griñán-Ferré
Frontiers in Genetics. 2018; 9
[Pubmed] | [DOI]
185 The Emerging Role of microRNAs in Aquaporin Regulation
André Gomes,Inês V. da Silva,Cecília M. P. Rodrigues,Rui E. Castro,Graça Soveral
Frontiers in Chemistry. 2018; 6
[Pubmed] | [DOI]
186 miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma
Rui Suzuki,Vishwa Jeet Amatya,Kei Kushitani,Yuichiro Kai,Takahiro Kambara,Yukio Takeshima
Frontiers in Oncology. 2018; 8
[Pubmed] | [DOI]
187 Targeting Non-coding RNA in Vascular Biology and Disease
John Hung,Vladislav Miscianinov,Judith C. Sluimer,David E. Newby,Andrew H. Baker
Frontiers in Physiology. 2018; 9
[Pubmed] | [DOI]
188 MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
Kenneth KW To,Christy WS Tong,Mingxia Wu,William CS Cho
World Journal of Gastroenterology. 2018; 24(27): 2949
[Pubmed] | [DOI]
189 MicroRNA-124-3p attenuates severe community-acquired pneumonia progression in macrophages by targeting tumor necrosis factor receptor-associated factor 6
Wei Gao,Hongxia Yang
International Journal of Molecular Medicine. 2018;
[Pubmed] | [DOI]
190 MicroRNA-766 inhibits the malignant biological behaviours of pancreatic ductal adenocarcinoma by directly targeting ETS1
Shiquan Li,Guoqiang Yan,Meng Yue,Zhenhua Kang,Lei Wang
Molecular Medicine Reports. 2018;
[Pubmed] | [DOI]
191 Establishment of an miR-137-knockout cell model using CRISPR/Cas9 genome editing
Wei Chen,Qi Li,Jingjie Du,Xiaodi Li,Songshan Jiang,Yuanli He
Oncology Letters. 2018;
[Pubmed] | [DOI]
192 Role of Non-Coding RNAs in the Etiology of Bladder Cancer
Caterina Gulìa,Stefano Baldassarra,Fabrizio Signore,Giuliano Rigon,Valerio Pizzuti,Marco Gaffi,Vito Briganti,Alessandro Porrello,Roberto Piergentili
Genes. 2017; 8(12): 339
[Pubmed] | [DOI]
193 Non-coding RNA Contribution to Thoracic and Abdominal Aortic Aneurysm Disease Development and Progression
Yuhuang Li,Lars Maegdefessel
Frontiers in Physiology. 2017; 8
[Pubmed] | [DOI]
194 Hypoxia in CNS Pathologies: Emerging Role of miRNA-Based Neurotherapeutics and Yoga Based Alternative Therapies
Gillipsie Minhas,Deepali Mathur,Balakrishnan Ragavendrasamy,Neel K. Sharma,Viraaj Paanu,Akshay Anand
Frontiers in Neuroscience. 2017; 11
[Pubmed] | [DOI]
195 Noncoding RNA in drug resistant sarcoma
Xiaoyang Li,Jacson K. Shen,Francis J. Hornicek,Tao Xiao,Zhenfeng Duan
Oncotarget. 2017; 8(40): 69086
[Pubmed] | [DOI]
196 microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application
Véronique Desgagné,Luigi Bouchard,Renée Guérin
Clinical Chemistry and Laboratory Medicine (CCLM). 2017; 55(5)
[Pubmed] | [DOI]
197 microRNAs in cardiovascular disease – clinical application
Christian Schulte,Mahir Karakas,Tanja Zeller
Clinical Chemistry and Laboratory Medicine (CCLM). 2017; 55(5)
[Pubmed] | [DOI]
198 miRNA analysis in pancreatic cancer: the Dartmouth experience
Francine B. de Abreu,Xiaoying Liu,Gregory J. Tsongalis
Clinical Chemistry and Laboratory Medicine (CCLM). 2017; 55(5)
[Pubmed] | [DOI]
199 Regulatory role of microRNA on inflammatory responses of diabetic retinopathy
Eun-Ah Ye,JenaJ Steinle
Neural Regeneration Research. 2017; 12(4): 580
[Pubmed] | [DOI]
200 A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma
Afshin Beheshti,Charles Vanderburg,J. Tyson McDonald,Charusheila Ramkumar,Tatenda Kadungure,Hong Zhang,Ronald B. Gartenhaus,Andrew M. Evens,Jianjun Zhao
PLOS ONE. 2017; 12(1): e0170521
[Pubmed] | [DOI]
201 Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy
Viorel Simion,Julien Sobilo,Rudy Clemoncon,Sharuja Natkunarajah,Safia Ezzine,Florence Abdallah,Stephanie Lerondel,Chantal Pichon,Patrick Baril,Juri G. Gelovani
PLOS ONE. 2017; 12(5): e0177492
[Pubmed] | [DOI]
202 I?K-16 decreases miRNA-155 expression and attenuates the human monocyte inflammatory response
Norman James Galbraith,James Burton,Mathew Brady Ekman,Joseph Kenney,Samuel Patterson Walker,Stephen Manek,Campbell Bishop,Jane Victoria Carter,Sarah Appel Gardner,Hiram C. Polk,Partha Mukhopadhyay
PLOS ONE. 2017; 12(9): e0183987
[Pubmed] | [DOI]
203 T-ALL and thymocytes: a message of noncoding RNAs
Annelynn Wallaert,Kaat Durinck,Tom Taghon,Pieter Van Vlierberghe,Frank Speleman
Journal of Hematology & Oncology. 2017; 10(1)
[Pubmed] | [DOI]
204 Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek,Piotr S. Kowalski,Daniel G. Anderson
Genome Medicine. 2017; 9(1)
[Pubmed] | [DOI]
205 MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells
Daniela M. Gomez Zubieta,Mohamed A. Hamood,Rami Beydoun,Ashley E. Pall,Kalyan C. Kondapalli
Cell Communication and Signaling. 2017; 15(1)
[Pubmed] | [DOI]
206 The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection
Matthias Hamdorf,Satoru Kawakita,Matthew Everly
Journal of Immunology Research. 2017; 2017: 1
[Pubmed] | [DOI]
207 Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs
María Antonia Lizarbe,Jorge Calle-Espinosa,Eva Fernández-Lizarbe,Sara Fernández-Lizarbe,Miguel Ángel Robles,Nieves Olmo,Javier Turnay
BioMed Research International. 2017; 2017: 1
[Pubmed] | [DOI]
208 miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Joel Pekow,Katherine Meckel,Urszula Dougherty,Yong Huang,Xindi Chen,Anas Almoghrabi,Reba Mustafi,Fatma Ayaloglu-Butun,Zifeng Deng,Haider I. Haider,John Hart,David T. Rubin,John H. Kwon,Marc Bissonnette
Clinical Cancer Research. 2017; 23(17): 5281
[Pubmed] | [DOI]
209 MicroRNAs as future therapeutic targets in COPD?
Ken R. Bracke,Pieter Mestdagh
European Respiratory Journal. 2017; 49(5): 1700431
[Pubmed] | [DOI]
210 Role of microRNAs in obesity and obesity-related diseases
Giuseppe Iacomino,Alfonso Siani
Genes & Nutrition. 2017; 12(1)
[Pubmed] | [DOI]
211 miRNA-200c-3p is crucial in acute respiratory distress syndrome
Qiang Liu,Jianchao Du,Xuezhong Yu,Jun Xu,Fengming Huang,Xiaoyun Li,Cong Zhang,Xiao Li,Jiahui Chang,Daozhen Shang,Yan Zhao,Mingyao Tian,Huijun Lu,Jiantao Xu,Chang Li,Huadong Zhu,Ningyi Jin,Chengyu Jiang
Cell Discovery. 2017; 3: 17021
[Pubmed] | [DOI]
212 Dysregulated miRNAs and their pathogenic implications for the neurometabolic disease propionic acidemia
Ana Rivera-Barahona,Alejandro Fulgencio-Covián,Celia Pérez-Cerdá,Ricardo Ramos,Michael A. Barry,Magdalena Ugarte,Belén Pérez,Eva Richard,Lourdes R Desviat
Scientific Reports. 2017; 7(1)
[Pubmed] | [DOI]
213 High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?
Yngve Nordby,Elin Richardsen,Nora Ness,Tom Donnem,Hiten R. H. Patel,Lill-Tove Busund,Roy M. Bremnes,Sigve Andersen
Scientific Reports. 2017; 7(1)
[Pubmed] | [DOI]
214 Inflammation-induced miRNA-155 inhibits self-renewal of neural stem cells via suppression of CCAAT/enhancer binding protein ß (C/EBPß) expression
Kayoko Obora,Yuta Onodera,Toshiyuki Takehara,John Frampton,Joe Hasei,Toshifumi Ozaki,Takeshi Teramura,Kanji Fukuda
Scientific Reports. 2017; 7: 43604
[Pubmed] | [DOI]
215 MiR-138-5p targeting LIMK1 suppresses breast cancer cell proliferation and motility
Dengfeng Li,Hongming Song,Tianqi Wu,Dan Xie,Jiashu Hu,Junyong Zhao,Lin Fang
RSC Advances. 2017; 7(82): 52030
[Pubmed] | [DOI]
216 MicroRNAs in the skin: role in development, homoeostasis and regeneration
Steven Horsburgh,Nicola Fullard,Mathilde Roger,Abbie Degnan,Stephen Todryk,Stefan Przyborski,Steven O’Reilly
Clinical Science. 2017; 131(15): 1923
[Pubmed] | [DOI]
217 TGFß as a therapeutic target in cystic fibrosis
Elizabeth L. Kramer,John P. Clancy
Expert Opinion on Therapeutic Targets. 2017; : 1
[Pubmed] | [DOI]
218 Shields Up—Systemic Protection Provided by microRNA-21 During Sepsis?*
Cliona Ni Cheallaigh,Frederick J. Sheedy
Critical Care Medicine. 2017; 45(7): 1261
[Pubmed] | [DOI]
219 Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDL cholesterol in murine diet-induced dyslipidemia
Alisha R. Coffey,Tangi L. Smallwood,Jody Albright,Kunjie Hua,Matt Kanke,Daniel Pomp,Brian J. Bennett,Praveen Sethupathy
Physiological Genomics. 2017; 49(11): 618
[Pubmed] | [DOI]
220 New Dancing Couple: PD-L1 and MicroRNA
A. Grenda,P. Krawczyk
Scandinavian Journal of Immunology. 2017; 86(3): 130
[Pubmed] | [DOI]
221 Inflammasome Priming in Sterile Inflammatory Disease
Meghana N. Patel,Richard G. Carroll,Silvia Galván-Peña,Evanna L. Mills,Robin Olden,Martha Triantafilou,Amaya I. Wolf,Clare E. Bryant,Kathy Triantafilou,Seth L. Masters
Trends in Molecular Medicine. 2017; 23(2): 165
[Pubmed] | [DOI]
222 The roles of non-coding RNAs in cardiac regenerative medicine
Oi Kuan Choong,Desy S. Lee,Chen-Yun Chen,Patrick C.H. Hsieh
Non-coding RNA Research. 2017;
[Pubmed] | [DOI]
223 MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model
Jinshan Shi,Ke Jiang,Zhaoduan Li
Neuroscience Research. 2017;
[Pubmed] | [DOI]
224 Small non coding RNAs in adipocyte biology and obesity
Ez-Zoubir Amri,Marcel Scheideler
Molecular and Cellular Endocrinology. 2017;
[Pubmed] | [DOI]
225 Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy
Cristina R. Reschke,Luiz F. Almeida Silva,Braxton A. Norwood,Ketharini Senthilkumar,Gareth Morris,Amaya Sanz-Rodriguez,Ronán M. Conroy,Lara Costard,Valentin Neubert,Sebastian Bauer,Michael A. Farrell,Donncha F. O’Brien,Norman Delanty,Stephanie Schorge,R. Jeroen Pasterkamp,Felix Rosenow,David C. Henshall
Molecular Therapy - Nucleic Acids. 2017; 6: 45
[Pubmed] | [DOI]
226 Epigenetics in multiple myeloma: From mechanisms to therapy
Mohammad Alzrigat,Alba Atienza Párraga,Helena Jernberg-Wiklund
Seminars in Cancer Biology. 2017;
[Pubmed] | [DOI]
227 MicroRNA-467g inhibits new bone regeneration by targeting Ihh/Runx-2 signaling
Jyoti Kureel,Aijaz A John,Manisha Dixit,Divya Singh
The International Journal of Biochemistry & Cell Biology. 2017;
[Pubmed] | [DOI]
228 MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma
Sohair M. Salem,Ahmed R. Hamed,Rehab M. Mosaad
Biomedicine & Pharmacotherapy. 2017; 94: 767
[Pubmed] | [DOI]
229 miR-497 accelerates oxidized low-density lipoprotein-induced lipid accumulation in macrophages by repressing the expression of apelin
Junfeng Cui,Zhong Ren,Wenshuang Zou,Yanling Jiang
Cell Biology International. 2017; 41(9): 1012
[Pubmed] | [DOI]
230 Role of miRNAs in human disease and inborn errors of metabolism
Ana Rivera-Barahona,Belén Pérez,Eva Richard,Lourdes R. Desviat
Journal of Inherited Metabolic Disease. 2017;
[Pubmed] | [DOI]
231 Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers
Maryam Honardoost,Seyed Mohammad Ali Hosseini Rad
Applied Biochemistry and Biotechnology. 2017;
[Pubmed] | [DOI]
232 A Concise Review of MicroRNA Exploring the Insights of MicroRNA Regulations in Bacterial, Viral and Metabolic Diseases
Ahsan Naveed,Sajjad ur-Rahman,Sabahat Abdullah,Muhammad Ammar Naveed
Molecular Biotechnology. 2017;
[Pubmed] | [DOI]
233 MicroRNAs in injury and repair
Cory V. Gerlach,Vishal S. Vaidya
Archives of Toxicology. 2017;
[Pubmed] | [DOI]
234 Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis
Lindsay R. Stolzenburg,Ann Harris
Cell and Tissue Research. 2017;
[Pubmed] | [DOI]
235 miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1
Nibedita Patel,Koteswara Rao Garikapati,M. Janaki Ramaiah,Kavi Kishor Polavarapu,Utpal Bhadra,Manika Pal Bhadra
Life Sciences. 2016;
[Pubmed] | [DOI]
236 Trying to understand the genetics of atopic dermatitis
Susanne Stemmler,Sabine Hoffjan
Molecular and Cellular Probes. 2016; 30(6): 374
[Pubmed] | [DOI]
237 MicroRNA-targeted therapeutics for lung cancer treatment
Jing Xue,Jiali Yang,Meihui Luo,William C. Cho,Xiaoming Liu
Expert Opinion on Drug Discovery. 2016; : 1
[Pubmed] | [DOI]
238 MicroRNA-29b Overexpression Decreases Extracellular Matrix mRNA and Protein Production in Human Corneal Endothelial Cells
Tetsuya Toyono,Tomohiko Usui,Guadalupe Villarreal,Laura Kallay,Mario Matthaei,Lucas M. M. Vianna,Angela Y. Zhu,Masahiko Kuroda,Shiro Amano,Albert S. Jun
Cornea. 2016; 35(11): 1466
[Pubmed] | [DOI]
239 Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
Ana I. Robles,Karina Standahl Olsen,Dana W.T. Tsui,Vassilis Georgoulias,Jenette Creaney,Katalin Dobra,Mogens Vyberg,Nagahiro Minato,Robert A. Anders,Anne-Lise Børresen-Dale,Jianwei Zhou,Pål Sætrom,Boye Schnack Nielsen,Michaela B. Kirschner,Hans E. Krokan,Vassiliki Papadimitrakopoulou,Ioannis Tsamardinos,Oluf D. Røe
Journal of Translational Medicine. 2016; 14(1)
[Pubmed] | [DOI]
240 Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
Armin Zebisch,Stefan Hatzl,Martin Pichler,Albert Wölfler,Heinz Sill
International Journal of Molecular Sciences. 2016; 17(12): 2080
[Pubmed] | [DOI]



 
Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   History
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed12615    
    Printed471    
    Emailed0    
    PDF Downloaded3058    
    Comments [Add]    
    Cited by others 240    

Recommend this journal
Sitemap | What's New | Feedback | Disclaimer | Privacy Notice
© Perspectives in Clinical Research | Published by Wolters Kluwer - Medknow
Online since 20th October, 2010